168 related articles for article (PubMed ID: 35364740)
1. Functional antigen processing and presentation mechanism as a prerequisite factor of response to treatment with dendritic cell vaccines and anti-PD-1 in preclinical murine LLC1 and GL261 tumor models.
Žilionytė K; Bagdzevičiūtė U; Mlynska A; Urbštaitė E; Paberalė E; Dobrovolskienė N; Krasko JA; Pašukonienė V
Cancer Immunol Immunother; 2022 Nov; 71(11):2691-2700. PubMed ID: 35364740
[TBL] [Abstract][Full Text] [Related]
2. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
[TBL] [Abstract][Full Text] [Related]
3. Editing the immunopeptidome of melanoma cells using a potent inhibitor of endoplasmic reticulum aminopeptidase 1 (ERAP1).
Koumantou D; Barnea E; Martin-Esteban A; Maben Z; Papakyriakou A; Mpakali A; Kokkala P; Pratsinis H; Georgiadis D; Stern LJ; Admon A; Stratikos E
Cancer Immunol Immunother; 2019 Aug; 68(8):1245-1261. PubMed ID: 31222486
[TBL] [Abstract][Full Text] [Related]
4. ERAP1-Dependent Antigen Cross-Presentation Determines Efficacy of Adoptive T-cell Therapy in Mice.
Schmidt K; Keller C; Kühl AA; Textor A; Seifert U; Blankenstein T; Willimsky G; Kloetzel PM
Cancer Res; 2018 Jun; 78(12):3243-3254. PubMed ID: 29559473
[TBL] [Abstract][Full Text] [Related]
5. MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells.
Leone P; Shin EC; Perosa F; Vacca A; Dammacco F; Racanelli V
J Natl Cancer Inst; 2013 Aug; 105(16):1172-87. PubMed ID: 23852952
[TBL] [Abstract][Full Text] [Related]
6. HLA class I is most tightly linked to levels of tapasin compared with other antigen-processing proteins in glioblastoma.
Thuring C; Follin E; Geironson L; Freyhult E; Junghans V; Harndahl M; Buus S; Paulsson KM
Br J Cancer; 2015 Sep; 113(6):952-62. PubMed ID: 26313662
[TBL] [Abstract][Full Text] [Related]
7. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
Front Immunol; 2019; 10():1505. PubMed ID: 31333652
[TBL] [Abstract][Full Text] [Related]
8. Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME).
Bretz AC; Parnitzke U; Kronthaler K; Dreker T; Bartz R; Hermann F; Ammendola A; Wulff T; Hamm S
J Immunother Cancer; 2019 Nov; 7(1):294. PubMed ID: 31703604
[TBL] [Abstract][Full Text] [Related]
9. Association of defective HLA-I expression with antigen processing machinery and their association with clinicopathological characteristics in Kazak patients with esophageal cancer.
Ayshamgul H; Ma H; Ilyar S; Zhang LW; Abulizi A
Chin Med J (Engl); 2011 Feb; 124(3):341-6. PubMed ID: 21362330
[TBL] [Abstract][Full Text] [Related]
10. Correction to: Functional antigen processing and presentation mechanism as a prerequisite factor of response to treatment with dendritic cell vaccines and anti-PD-1 in preclinical murine LLC1 and GL261 tumor models.
Žilionytė K; Bagdzevičiūtė U; Mlynska A; Urbštaitė E; Paberalė E; Dobrovolskienė N; Krasko JA; Pašukonienė V
Cancer Immunol Immunother; 2022 Nov; 71(11):2701. PubMed ID: 35467108
[No Abstract] [Full Text] [Related]
11. Qa-1
Zhang X; Sabio E; Krishna C; Ma X; Wang J; Jiang H; Havel JJ; Chan TA
Mol Cancer Res; 2021 Jun; 19(6):1076-1084. PubMed ID: 33674442
[TBL] [Abstract][Full Text] [Related]
12. Restoration by IL-15 of MHC class I antigen-processing machinery in human dendritic cells inhibited by tumor-derived gangliosides.
Tourkova IL; Shurin GV; Chatta GS; Perez L; Finke J; Whiteside TL; Ferrone S; Shurin MR
J Immunol; 2005 Sep; 175(5):3045-52. PubMed ID: 16116192
[TBL] [Abstract][Full Text] [Related]
13. MHC class I dysfunction of glioma stem cells escapes from CTL-mediated immune response via activation of Wnt/β-catenin signaling pathway.
Yang W; Li Y; Gao R; Xiu Z; Sun T
Oncogene; 2020 Jan; 39(5):1098-1111. PubMed ID: 31591480
[TBL] [Abstract][Full Text] [Related]
14. IFN-γ treatment protocol for MHC-I
Stifter K; Krieger J; Ruths L; Gout J; Mulaw M; Lechel A; Kleger A; Seufferlein T; Wagner M; Schirmbeck R
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32868392
[TBL] [Abstract][Full Text] [Related]
15. Rationally designed inhibitor targeting antigen-trimming aminopeptidases enhances antigen presentation and cytotoxic T-cell responses.
Zervoudi E; Saridakis E; Birtley JR; Seregin SS; Reeves E; Kokkala P; Aldhamen YA; Amalfitano A; Mavridis IM; James E; Georgiadis D; Stratikos E
Proc Natl Acad Sci U S A; 2013 Dec; 110(49):19890-5. PubMed ID: 24248368
[TBL] [Abstract][Full Text] [Related]
16. Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement.
Johnson DB; Nixon MJ; Wang Y; Wang DY; Castellanos E; Estrada MV; Ericsson-Gonzalez PI; Cote CH; Salgado R; Sanchez V; Dean PT; Opalenik SR; Schreeder DM; Rimm DL; Kim JY; Bordeaux J; Loi S; Horn L; Sanders ME; Ferrell PB; Xu Y; Sosman JA; Davis RS; Balko JM
JCI Insight; 2018 Dec; 3(24):. PubMed ID: 30568030
[TBL] [Abstract][Full Text] [Related]
17. IRF1 and NF-kB restore MHC class I-restricted tumor antigen processing and presentation to cytotoxic T cells in aggressive neuroblastoma.
Lorenzi S; Forloni M; Cifaldi L; Antonucci C; Citti A; Boldrini R; Pezzullo M; Castellano A; Russo V; van der Bruggen P; Giacomini P; Locatelli F; Fruci D
PLoS One; 2012; 7(10):e46928. PubMed ID: 23071666
[TBL] [Abstract][Full Text] [Related]
18. Potentially functional variants of ERAP1, PSMF1 and NCF2 in the MHC-I-related pathway predict non-small cell lung cancer survival.
Yang S; Tang D; Zhao YC; Liu H; Luo S; Stinchcombe TE; Glass C; Su L; Shen S; Christiani DC; Wang Q; Wei Q
Cancer Immunol Immunother; 2021 Oct; 70(10):2819-2833. PubMed ID: 33651148
[TBL] [Abstract][Full Text] [Related]
19. Interferon regulatory factor 8 mediates tumor-induced inhibition of antigen processing and presentation by dendritic cells.
Tourkova IL; Shurin GV; Ferrone S; Shurin MR
Cancer Immunol Immunother; 2009 Apr; 58(4):567-74. PubMed ID: 18751977
[TBL] [Abstract][Full Text] [Related]
20. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
